– USA, TX – Gradalis, a late-stage stage biotechnology company developing immunotherapies for multiple cancer indications, today announced the appointment of Steve Engle to its Board of Directors as CEO, bringing over two decades of executive leadership experience with public biotech companies developing breakthrough products in the metabolic, autoimmune, oncologic and infectious disease areas.
He succeeds founder David Shanahan, who will continue as Board Chair.
“Steve is a highly accomplished healthcare executive, and we are especially happy to have him leading the Gradalis team at this important time in the company’s evolution,” said Board Chair, David Shadnahan. “We expect that Steve’s extensive experience in R&D and commercialization, together with his track record of executing value-creating strategic transactions, will be instrumental in achieving our corporate and clinical goals.”
About Steven Engle
Before joining Gradalis, Steve Engle served as CEO of CohBar, a clinical-stage mitochondria-based therapeutics developer, and CEO and Board Chair of XOMA, an antibody therapeutics company that helped develop products with multiple pharmaceutical companies including Novartis, Merck, Pfizer, and Takeda. Before XOMA, Mr. Engle served as CEO and Board Chair of La Jolla Pharmaceutical Company, which was the first to discover the biology of B cell tolerance, developed the first B cell toleragen for lupus patients, and received an approvable letter from the FDA. While at drug delivery systems company Cygnus, he helped gain FDA approval for and launch Nicotrol for smoking cessation.
Mr. Engle currently serves on the Board of Prescient Therapeutics Ltd., AROA Biosurgery Ltd, and Author-it Software Corporation. He is a former director of BIO, BayBio, and BIOCOM. Mr. Engle holds M.S.E.E. and B.S.E.E. degrees from The University of Texas with a focus in biomedical engineering.
About Gradalis, Inc.
Gradalis is a late-stage clinical biotechnology company developing immunotherapies for multiple cancer indications including an upcoming Phase 3 registration trial in patients with ovarian cancer. The company’s proprietary bi-shRNA therapy platform, proven in its clinical studies, can be utilized to silence a broad range of genes and apply to multiple cancer types.
For more information: https://www.gradalisinc.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.